VBI Vaccines Inc (NASDAQ:VBIV) is making a strong move in the early session on Wednesday. The stock has been witnessing a nice uptrend since over the past week with a jump of around 21%. Will the Rally continue?
Major Trigger:
VBI Vaccines Announces Multiple Abstracts Accepted for Poster Presentations at EASL 2021
Key Highlights:
- today announced that two abstracts featuring data from the Company’s prophylactic and therapeutic hepatitis B (HBV) candidates have been accepted for presentation at The Digital International Liver Congress™ 2021 (ILC), the Annual Meeting of the European Association for the Study of the Liver (EASL), taking place June 23-26, 2021.
- Hepatitis B is one of the world’s most significant infectious disease threats with more than 290 million people infected globally. HBV infection is the leading cause of liver disease and, with current treatments, it is very difficult to cure, with many patients going on to develop liver cancers. An estimated 900,000 people die each year from complications of chronic HBV such as liver decompensation, cirrhosis, and hepatocellular carcinoma.
- VBI-2601 (BRII-179) is a novel recombinant, protein-based HBV immunotherapeutic candidate that builds upon the 3-antigen conformation of VBI’s prophylactic 3-antigen HBV vaccine candidate, and is designed to target enhanced B-cell and T-cell immunity. VBI-2601 (BRII-179) is being developed in collaboration with Brii Biosciences in the licensed territory of China, Hong Kong, Macau, and Taiwan as part of a potential functional cure for chronic hepatitis B infection.
Market Reaction
As of 10:05, VBIV stock moved up by 4.80% to $4.15 with more than 1.85 million shares traded hands, compared to its average volume of 3.56 million shares. The stock has moved within a range of $ 3.9400 – 4.1800 after opening the trade at $3.99.
){kind=link}